Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, discusses the role of biomarkers in chronic lymphocytic leukemia (CLL), explaining that prognostic markers are used to indicate clinical outcomes regardless of the therapy used, whereas predictive biomarkers can help determine a patient’s outcome to a specific therapy. With an emphasis on Ig gene mutations and TP53 aberrations as the most informative biomarkers in CLL, decisions on therapeutic approaches and risk stratification can be made by performing genomic testing on patients with CLL. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.